

AMENDMENT TO THE CLAIMS

1. - 216. (Cancelled)

217. (Currently Amended) A method for inhibiting growth of a cancer cell, the method comprising:

providing a linear polypeptide comprising an amino acid sequence, said amino acid sequence being selected from the group consisting of 1) an amino acid sequence defining a binding domain of a β integrin subunit for ERK2 MAP kinase, said binding domain comprising an intervening, centrally located amino acid linker sequence that links opposite terminal end amino acid sequence regions of the binding domain together and is non-essential for binding of the MAP kinase to said binding domain, the amino acid sequence defining the binding domain being selected from the group consisting of RSKAKWQTGTNPLYR (SEQ ID No. 2), RARAKWDTANNPLYK (SEQ ID No. 22) and RSRARYEMASNPLYR (SEQ ID No. 23); and 2) an amino acid sequence defining the binding domain as specified in (1) wherein or wherein the linker sequence of the binding domain is deleted in the polypeptide such that the opposite terminal end amino acid sequence regions of the binding domain remain and are contiguous with one another in the polypeptide, the amino acid sequence defining the binding domain being selected from the group consisting of RSKAKWQTGTNPLYR (SEQ ID No. 2), RARAKWDTANNPLYK (SEQ ID No. 22) and RSRARYEMASNPLYR (SEQ ID No. 23); and

treating a cancer cell with an effective amount of said polypeptide to inhibit the growth of the cancer cell.

218. (Previously Presented) A method according to claim 217, wherein the polypeptide is coupled to a facilitator moiety that facilitates passage of the polypeptide across the outer cell membrane of the cancer cell into the cancer cell.

219. (Currently Amended) A method according to claim 217 or 218, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of RSKAKWQTGTNPLYR (SEQ ID No. 2) and RSKAKNPLYR (SEQ ID No. 3).

220 - 224. (Cancelled)

225. (Previously Presented) A method according to claim 217 wherein the cancer cell is a colon cancer cell.

226 - 237. (Cancelled)

238. (Previously Presented) A method according to claim 217, wherein the cancer cell is a cancer cell of a cancer selected from the group consisting of cancer of the lip, tongue, salivary glands, gums, floor of the mouth, oropharynx, nasopharynx, hypopharynx, oesophagus, stomach, small intestine, duodenum, colon, rectum, gallbladder, pancreas, larynx, trachea, bronchus, lung, breast, uterus, cervix, ovary, vagina, vulva, prostate, testes, penis, bladder, kidney, thyroid and skin.

239-276. (Cancelled)

277. (Currently Amended) A method according to claim 217, 218 or 219, wherein the polypeptide is ~~up to~~ between 10 and 25 amino acids in length.

278-287. (Cancelled)